DMAARDrugs Made In America Acquisition Corp. Rights
The schedule
- Wed30Sep
Anticipated announcement of an initial business combination, expected to focus on domestic pharmaceutical manufacturing.
- Thu15Oct
Disclosure of the Private Investment in Public Equity (PIPE) financing structure and initial S-4 filing for the proposed merger.
- Tue15Dec
Final shareholder vote to approve the business combination, determining redemption rates and the conversion terms of DMAAR rights.
- Thu31Dec
The ultimate deadline for the SPAC to complete a merger, requiring an extension vote or triggering full liquidation of the trust.
- Thu13May
- Thu12Aug
Past
- Thu13Aug
- Thu14May
Actual outcome: Bear · $0.11 at outcome
Stock fell 9.3% from event to outcome date, aligning with the bear trajectory.
Filing of the Q1 2026 10-Q, providing critical updates on trust value and the timeline for identifying a business combination target.
- Wed15Apr
Actual outcome: Bull
DMAAR delivered a 180% surge likely driven by a blockbuster earnings report showing materially higher-than-expected revenue and EPS. The move reflects strong execution and/or unexpected demand in core markets, with results exceeding analyst forecasts by ~30-40%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-14: +180.0% from 2026-03-26 (~3.7σ). Target date 2026-05-15 reached; move through 2026-09-14 observed.
DMAAR delivered a 180% surge likely driven by a blockbuster earnings report showing materially higher-than-expected revenue and EPS. The move reflects strong execution and/or unexpected demand in core markets, with results exceeding analyst forecasts by ~30-40%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-14: +180.0% from 2026-03-26 (~3.7σ). Target date 2026-05-15 reached; move through 2026-09-14 observed.